Simbe Robotics Unveils Revolutionized Store Intelligence Platform
Simbe Robotics Inc. has recently launched an updated version of its Store Intelligence platform, …
12. August 2025
HistoSonics, a leading developer of non-invasive sonic beam therapy using histotripsy, has reached a significant milestone with the announcement that it has been acquired by a management-led syndicate of private and public investors. The transaction valued HistoSonics at approximately $2.25 billion, positioning the company for accelerated growth of its Edison System across new clinical indications and global markets.
The acquisition, which was completed last week, saw K5 Global, Bezos Expeditions, Wellington Management, and other prominent investors join forces to support HistoSonics’ mission to revolutionize the treatment of various medical conditions. Mike Blue, the company’s president and CEO since its inception in 2009, will continue to lead the organization, taking on an additional role as chairman of the board upon closing.
HistoSonics’ focus on speed, scale, and urgency has been unwavering, with the goal of offering patients a better option than any they have today. According to Blue, the new group of partners backs category-defining companies that transform entire industries, providing HistoSonics with the firepower to accelerate its momentum, expand into new clinical indications, and reach even more patients around the world who urgently need its breakthrough therapy.
The company’s 16 years of histotripsy experience has been instrumental in its development of a non-invasive platform and proprietary sonic beam therapy. This novel mechanism of action uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors, offering a promising alternative to traditional treatments. HistoSonics is currently focusing on commercializing Edison in the U.S. and select global markets for liver treatment, with offices in Ann Arbor, Mich., and Minneapolis.
In October 2023, the U.S. Food and Drug Administration granted HistoSonics de novo clearance for its robotic system, marking a significant milestone in the company’s journey. To date, more than 2,000 patients have been treated by the Edison system at over 50 leading U.S. medical centers, with another 50 planned system installations by year’s end. This success has been accompanied by growing interest from hospitals and patients alike, with the company announcing in June that Edison secured limited U.K. market access.
The acquisition of HistoSonics is a testament to the company’s rapid progress and the potential of histotripsy technology. With the support of its new investors, HistoSonics plans to expand beyond its initial focus on liver tumors to preclinical and clinical research for kidney, pancreas, and prostate indications. The long-term vision is to use histotripsy across a wide range of clinical applications throughout the body, treating both benign and malignant conditions.
“What stood out with HistoSonics wasn’t just the technology; it was the speed and clarity with which the team turned a breakthrough into real clinical traction,” said Bryan Baum, co-founder and managing partner of K5 Global. “Hospitals are continuing to order systems, patient demand is surging, and the clinical results speak for themselves.”
Johnson & Johnson supported HistoSonics through its corporate venture capital organization, Johnson & Johnson – JJDC Inc., demonstrating the growing interest in innovative medical technologies. As HistoSonics embarks on this new chapter, it is clear that the company’s commitment to speed, scale, and urgency will continue to drive its success.
HistoSonics is currently enrolling patients in clinical trials for liver tumors, kidney tumors (HOPE4KIDNEY Trial NCT05820087), and pancreas tumors (GANNON Trial NCT06282809). It plans to start more trials in the near future, further solidifying its position as a leader in the field of histotripsy.
The investment in HistoSonics positions the company for significant growth and expansion into new clinical indications and global markets. The company’s focus on innovation and its commitment to delivering breakthrough therapy to patients will continue to drive its success. With a strong team in place, including Mike Blue as president and CEO, HistoSonics is well-positioned to make a significant impact in the medical technology landscape.
As HistoSonics continues to push the boundaries of histotripsy technology, it is clear that this acquisition marks an exciting new chapter in the company’s journey. The future looks bright, with a strong focus on expanding its Edison System across new clinical indications and global markets. With the support of its new investors, HistoSonics is poised to accelerate its growth and expand its reach into new clinical indications and global markets.
The acquisition of HistoSonics by a management-led syndicate of private and public investors marks an exciting new chapter in the company’s journey, with a strong focus on innovation and delivering breakthrough therapy to patients. The investment positions the company for significant growth and expansion into new clinical indications and global markets, with a focus on innovation and delivering breakthrough therapy to patients.
With the support of its new investors, HistoSonics is poised to accelerate its growth and expand its reach into new clinical indications and global markets. The company’s Edison System has already shown promising results, with over 2,000 patients treated at over 50 leading U.S. medical centers. As HistoSonics continues to push the boundaries of histotripsy technology, it is clear that this acquisition marks an exciting new chapter in the company’s journey.
The future of HistoSonics looks bright, with a strong focus on expanding its Edison System across new clinical indications and global markets. The company’s commitment to innovation and its dedication to delivering breakthrough therapy to patients will continue to drive its success. With the support of its new investors, HistoSonics is well-positioned to make a significant impact in the medical technology landscape.
As HistoSonics embarks on this new chapter, it is clear that the company’s focus on speed, scale, and urgency will continue to drive its growth and expansion into new clinical indications and global markets. The Edison System has already shown promising results, with over 2,000 patients treated at over 50 leading U.S. medical centers. With the support of its new investors, HistoSonics is poised to accelerate its growth and expand its reach into new clinical indications and global markets.
HistoSonics’ commitment to innovation and its focus on delivering breakthrough therapy to patients will continue to drive its success. The investment in HistoSonics positions the company for significant growth and expansion into new clinical indications and global markets, with a strong team in place, including Mike Blue as president and CEO.
The acquisition of HistoSonics by a management-led syndicate of private and public investors marks an exciting new chapter in the company’s journey, with a focus on innovation and delivering breakthrough therapy to patients. The investment will enable HistoSonics to accelerate its growth and expand into new markets, further solidifying its position as a leader in histotripsy technology.
With the support of its new investors, HistoSonics is well-positioned to make a significant impact in the medical technology landscape. The future looks bright, with a strong focus on expanding its Edison System across new clinical indications and global markets.